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https://doi.org/10.1016/j.jtho.2019.06.011ABSTRACT
Lung cancer remains the leading cause of cancer-related mor-
tality worldwide. Tobacco consumption remains the most
important risk factor. Although the prevalence of smoking has
decreased overall, it continues to be a significant burden for
global health. It is estimated that there are still nearly 1 billion
cigarette smokers worldwide. Prevention strategies have
largely focused on tobacco control and prevention. However,
wehavewitnessedadramatic increase in theuseof e-cigarettes
and other vaping products. Primary chemoprevention has
historically not been a successful strategy for lung cancer;
however, focused approaches in specific groups of patients at
high risk for development of lung cancer are underway. The
majority of cases with NSCLC are diagnosed with locally
advanced or metastatic disease, where the overall prognosis
remains very poor. Early-stage NSCLC on the other hand has a
muchbetterprognosis andcanusuallybe treatedradicallywith
either surgical resectionor radical radiotherapy,with relatively
favorable long-term outcomes. In addition to image-based
screening, other methods such as breath-based and biofluid-
based approaches are now being investigated for early detec-
tionofNSCLC.This reviewwill focusonrecent advancements in
thefield of prevention, screening, and early detection ofNSCLC.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Lung cancer remains the leading cause of cancer
related mortality responsible for one in five cancer-
related deaths worldwide. Although smoking rates
have decreased across the world, the incidence of lung
cancer has plateaued with an estimated 1.8 million new
cases expected to be diagnosed globally in 2019.1 In the
United States alone, 228,150 new cases are expected
over the next year.2 There is a major unmet need for the
development of effective prevention, screening, andJournal of Thoracic Oncology Vol. 14 No. 9: 1513-1527
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Figure 1. Strategy of prevention (red) using smoking cessa-
tion, tobacco treatment, and chemoprevention. Early
detection approaches (purple) involving risk assessment and
images– based screening, breath-based and biofluid
screening, and early diagnostic approaches.
1514 Balata et al Journal of Thoracic Oncology Vol. 14 No. 9early detection methods. Tobacco is the leading carcin-
ogen. With nearly 90% of lung cancer attributable to
cigarette smoking, tobacco control remains essential to
reducing lung cancer morbidity and mortality.3 Despite
decades of progress in reducing overall cigarette con-
sumption, tobacco remains a real challenge due to the
emergence of other combustible tobacco products
including cigars, hookah, and noncombustible tobacco
products such as electronic cigarettes (also known as
e-cigarettes, e-cigs, electronic nicotine delivery system
[ENDS], or vapes). In recent years, discussion of new
tobacco products other than cigarettes has focused
largely on e-cigarettes, an ENDS that has emerged as a
potential alternative to combustible cigarettes and a
potential aid to smoking cessation. The long-term effects
of e-cigarettes on smoking cessation and general health
remain unknown. Smoking cessation is the most effec-
tive intervention for lung cancer prevention and pro-
grams are now in place to offer counseling, support, and
treatment of tobacco addiction. Chemoprevention,
defined as the use of natural or synthetic agents to
prevent, delay, or reverse carcinogenic progression to
invasive cancer has been successfully implemented in
various other malignancies, but trials have not been
successful in primary or secondary prevention of lung
cancer.
Based on the results of the National Lung Cancer
Screening Trial (NLST), in 2013, the United States Pre-
ventative Services Task Force (USPSTF) changed its
long-standing stance that there was insufficient evidence
to recommend low-dose computed tomography (LDCT)
screening for lung cancer and current guidelines in the
United States now recommend annual screening for lung
cancer with LDCT in adults aged 55 to 80 years who
have a 30 pack-year smoking history and currently
smoke or have quit within the past 15 years.4 Based on
data from this large trial and subsequent guidelines,
several U.S. centers incorporated programs to implement
LDCT screening and pulmonary nodule clinics. This was
a landmark development, as for the first time there was
direct evidence that we could actively use screening to
prevent lung cancer–related morbidity and mortality.
This past year we also witnessed results from the
population-based Dutch-Belgian NELSON trial which
showed that LDCT screening reduced lung cancer mor-
tality by 26% in men and 39% in women at 10 years.5
This, combined with the pre-existing evidence from
NLST, provides robust evidence that LDCT screening for
lung cancer in high-risk populations reduces disease-
specific mortality. One aspect of computed tomography
(CT) screening needing to be minimized is the potential
for false-positive findings. Noninvasive biomarkers,
including those found in breath, are currently under
development in an attempt to aid screening programs inreducing false-positive results. In addition, there have
been recent reports of using blood-based biomarkers to
identify patients at highest risk for development of lung
cancer.6,7
In this review, we provide the latest information from
recent publications and abstracts presented at major
academic meetings such as the World Conference on
Lung Cancer (WCLC), the American Association for
Cancer Research, the American Society of Clinical
Oncology, and the European Society of Medical Oncology.
The focus will be on the latest updates in prevention,
screening, and early detection of lung cancer including
smoking cessation, chemoprevention, screening, and
early diagnostic approaches (Fig. 1).
Lung Cancer Prevention
Smoking Cessation
With nearly 90% of the world’s lung cancers attrib-
utable to cigarette smoking, tobacco control remains
essential to reducing lung cancer morbidity and mor-
tality.3 Despite decades of progress in reducing cigarette
consumption, it is estimated that there are still nearly 1
billion cigarette smokers worldwide with 80% of current
smokers living in low- or middle-income countries.8 As
an example, in the United States there are an estimated
34 million smokers, representing 14% of the entire adult
September 2019 Prevention and Early Detection for Lung Cancer 1515population.9 Smoking remains higher among particular
populations including males; those with lower socio-
economic status; those with significant physical
disability or mental illness; lesbian, gay, bisexual, and
transgender persons; and certain racial and ethnic
groups.9 Even in low and medium Human Development
Index countries, cigarette consumption is associated
with lower socioeconomic status. These disparities in
adult smoking prevalence result in unequal tobacco-
related disease burden and represent formidable chal-
lenges for tobacco control.10 Although cigarette smoking
remains the most common form of tobacco use, dual and
poly-tobacco use has become more prevalent with the
recent emergence of other tobacco products (OTPs)
beyond cigarettes such as cigars, hookah, and noncom-
bustible tobacco products such as snus, e-cigarettes, and
heat-not-burns. More than 20% of cigarette smokers
older than the age of 15 years surveyed internationally
report concurrent use of combustible cigarettes and at
least one OTP.11 Although the effect of poly-tobacco use
on lung cancer remains unclear, there is an assumption
that tobacco control efforts to reduce or eliminate use of
combustible cigarettes will result in a decline in lung
cancer morbidity and mortality.
In recent years, discussion of OTPs has focused
largely on e-cigarettes, an ENDS that has emerged as an
alternative to combustible cigarettes and a potential aid
to smoking cessation. The long-term effects of e-cigarette
use remain unclear, especially among younger and
pregnant users.12 Most, although not all, public health
experts are of the opinion that switching completely
from cigarette smoking to using e-cigarettes would be
expected to reduce smoking-related health risks
including that of lung cancer.13-15 Adult smokers
commonly report using e-cigarettes in an attempt to stop
smoking, but evidence is limited regarding their actual
effectiveness in achieving smoking abstinence.16 Results
from a recently completed randomized controlled trial
(RCT) conducted in the United Kingdom found that
e-cigarettes were more effective for smoking cessation
than nicotine-replacement therapy when both products
were accompanied by behavioral support.17 Although
these findings are extremely encouraging, more research
is needed on the potential benefits and harms of e-cig-
arettes to inform and influence smoking cessation
guidelines and tobacco control policy. In particular, the
dramatic surge in sales and use of e-cigarettes among
youths is concerning because of the known adverse ef-
fects of nicotine on the developing brain and the un-
known impact of youth e-cigarette use on adulthood
smoking and health.18,19
Worldwide implementation of comprehensive to-
bacco control remains essential for achieving success in
reducing the overall tobacco-related disease burden.Leveraging the well-established public health advances
in vaccination, King and Graffunder20 summarized best
practices in global tobacco control by incorporating four
evidence-based population health components including
(1) tobacco price increases, (2) smoke-free policies, (3)
hard-hitting media campaigns, and (4) access to cessa-
tion treatment. There continues to be robust evidence
that strong tobacco control policies reduce smoking
prevalence and disease burden. Improving access to
evidence-based tobacco addiction treatment including
cessation medications and behavioral counseling is
essential. Along these lines, the Global Bridges Health-
care Alliance for Tobacco Dependence Treatment has
provided funding to address the global tobacco treat-
ment delivery barriers faced by low- and middle-income
communities including the need for tobacco treatment
training for health care providers and, as a result, to
date, approximately 9000 health care providers in low-
and middle-income communities worldwide have been
trained in tobacco dependence treatment.21Lung Cancer Treatment and Smoking Cessation
Historically acknowledged as central to primary
prevention of lung and other tobacco-related cancers,
there is now compelling data for tertiary prevention with
evidence that continued tobacco use has multiple
adverse effects on cancer treatment outcomes including
reduced survival, greater probability of recurrence, sec-
ond primary malignancies, greater symptom burden, and
poorer quality of life.3,22 Additionally, a recent report has
shown a potential $3.4 billion incremental cost of
treating cancer failures associated with continued
smoking among patients with cancer in the United States
each year.23 As such, most leading cancer organizations,
including the International Association for the Study of
Lung Cancer (IASLC), strongly endorse advising patients
to quit smoking and establishing evidence-based tobacco
treatment delivery as an indicator of high-quality cancer
care.24-26 Although a recent lung cancer provider survey
conducted by IASLC showed strong endorsement for the
importance of smoking cessation for cancer patients, it
has not yet been adopted widely as a standard of care.27
There are several new U.S. initiatives underway focused
on supporting effective implementation of smoking
cessation in routine cancer care.28 In partnership, the
American Association for Cancer Research and the Na-
tional Cancer Institute convened a task force that has
recommended standard tobacco use definitions and an
assessment tool (the Cancer Tobacco Use Questionnaire)
that can be used in cancer research and clinical set-
tings.29 In 2017, the National Cancer Institute launched
the Cancer Center Cessation Initiative (C3I) with the
long-term goal of helping cancer centers build and
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programs to routinely address smoking cessation with
cancer patients.30 Through C3I, multidisciplinary imple-
mentation teams will conduct quality improvement
studies focusing on overcoming patient, clinician, clinic,
and health system barriers, refining electronic medical
records and clinical workflows to ensure the systematic
identification and documentation of smokers and the
routine delivery of evidence-based tobacco cessation
treatment services. These and other studies underway
will provide a much-needed blueprint for feasible,
acceptable, and sustainable tobacco treatment delivery
in lung cancer care.Chemoprevention
Chemoprevention, defined as the use of natural or
synthetic agents to prevent, delay, or reverse carcino-
genic progression to invasive cancer has been success-
fully implemented in various malignancies. Based on the
success of selective estrogen receptor modulators in
preventing and reducing the risk of breast cancer and
the use of aspirin to reduce the incidence of colon cancer,
there has been an interest to develop similar strategies
to prevent the development of lung cancer. Our under-
standing of the molecular and biological basis of lung
cancer has increased considerably over the past 2 de-
cades, which has greatly improved our ability to develop
interventions aimed at reducing incidence of cancer.
Building on pre-clinical evidence that the prostaglandin
pathway is altered in a subset of subjects with squamous
cell lung cancer, a clinical trial of iloprost was designed
for lung cancer chemoprevention. The primary objective
of this trial was to compare the reversal of premalignant
histologic changes in the bronchial epithelium of patients
at high risk for lung cancer (defined as >20 pack years of
smoking with sputum atypia or endobronchial dysplasia)
treated with iloprost versus placebo. Using a combina-
tion of the average score of all bronchial biopsy results,
the worst biopsy score, and the dysplasia index, an
improvement was seen in former smokers but not in
current smokers.31 Other chemoprevention trials using
agents such as sulforaphane (NCT03232138), Lovaza
(made with fish oils) plus curcumin C3 complex
(NCT03598309) and are ongoing as well as work eval-
uating the role of immunotherapy in this setting.Pre-Neoplasia and Its Role in Prevention
In contrast to the dramatic explosion of knowledge
on cancer genomics from recent technological de-
velopments, much work is still needed in the study of
pre-neoplasia. Nonetheless we have seen advances over
the past year to consolidate and expand further the
pioneering work performed previously in this field.32Duruisseaux and Esteller33 undertook and published
a comprehensive review of epigenetic DNA hyper-
methylation of key genes, such as cyclin dependent ki-
nase inhibitor 2a (CDKN2A), death associated protein
kinase (DAPK), O-6-methylguanine-DNA methyltransfer-
ase (MGMT), retinoic acid receptor beta (RARb),
RASSF1A, and hTERT, during the process of progression
from normal cells to carcinoma. This article can be a
valuable resource to researchers keen on exploring the
role of epigenetic disruptions in lung cancer carcino-
genesis to realize the full potential these markers may
hold in the future for predicting risk, early diagnosis, and
potential treatments. Another important development
has been the identification of altered gene expression
profiles in 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK)–exposed normal appearing mouse air-
ways, partly modulated with smoking status in human
airway, and the finding that a candidate human bronchial
gene classifier is also enriched in the mouse airways.34
This potentially allows the use of such murine models
to not only understand human lung carcinogenesis but to
also help select the most promising chemoprevention
agents for human clinical trials. Also in 2018, Pan et al.35
provided a detailed description of methods which can be
used for obtaining repeated airway brushings in live
mice, that is, mimicking bronchoscopy in humans, to help
increase the research utility of experimental preneo-
plastic mouse models. Again, the novelty of such a mouse
model, which replicates what is done in humans, lies in
the potential of using such murine models to accelerate
testing of a wider range of candidate chemopreventive
agents and to better select those most likely to be im-
pactful in prerequisite clinical trials. Furthermore in this
topic, research by Kobayashi et al.36 has indicated that a
subset of KRAS- or BRAF-mutated ground-glass nodules
may undergo spontaneous regression, a paper intro-
duced by the legendary pathologist Dr. Adi Gazdar.37
Such observations confirm the wide spectrum of be-
haviors among ground-glass nodules and offer the
promise of new innovations that can perhaps initiate
natural regression of such disease. The potential for cure
by prevention cannot be underestimated. It is therefore
clear that there has been steady progress in lung pre-
neoplasia research over the past year with the hope of
translation to human benefit through prevention and/or
early diagnosis.Lung Cancer Early Detection
Risk Assessment
Screening for lung cancer through LDCT is different
from other screening programs such as those in breast
cancer or colorectal cancer where everyone above a
certain age group can be eligible. LDCT screening is more
September 2019 Prevention and Early Detection for Lung Cancer 1517of a process than just a test. It is a sensitive tool, but has
implications for downstream investigations including
further imaging, biopsies, and surgery. To maximize
benefits and minimize potential harms, accurate risk
assessment is needed to identify individuals with suffi-
cient risk most likely to benefit from LDCT screening.
Emerging data suggests the USPSTF- or NLST-like
criteria of age and smoking pack-years alone are sub-
optimal for identifying high-risk individuals for LDCT
screening.38 Only an estimated 40% of lung cancer pa-
tients in the U.S. and Canada would meet the USPSTF
screening criteria (patients 55 to 80 years old who had
smoked at least 30 pack-years and not starting screening
after 15 years of smoking abstinence) had screening
been available before diagnosis.39 Age and smoking
pack-years criteria also do not take into account racial
and ethnic differences. This is important as, for example,
African Americans have a higher incidence of lung cancer
after adjustment for important predictors such as
smoking.40 USPSTF risk selection criteria therefore does
not address health disparities among different
ethnicities.41
Lung cancer risk prediction tools can potentially in-
crease the sensitivity and positive predictive value of
screening selection criteria, reducing the number needed
to screen to avert one lung cancer death and improve
cost-effectiveness. There are at least 22 lung cancer risk
prediction tools published.42 One of the most accurate
prediction models is the Prostate, Lung, Colorectal and
Ovarian trial risk model 2012 version (PLCOm2012)
model that has been externally validated internation-
ally.43 The PLCOm2012 model addresses other risk factors
besides age and smoking such as ethnicity, chronic
obstructive pulmonary disease (COPD), family history of
lung cancer, and socioeconomic status. Retrospective
studies suggest the sensitivity to identify ever-smokers
at high risk of lung cancer for screening can be
improved to as high as 80% using such tools.43 However,
in a prospective study in a Canadian population with
newly diagnosed lung cancer between 2016 and 2018,
the sensitivity of the PLCOm2012 model was 63%,
compared to 45% using the USPSTF criteria, suggesting
additional work must be done to improve the accuracy of
risk prediction tools in ever-smokers.44 Another impor-
tant question to address in the future will be how to
select the most appropriate risk prediction model to use.
There are now two RCTs in progress to address this
question and prospectively compare different risk pre-
diction models, the International Lung Screening Trial
(ILST) and the Yorkshire Lung Screening Trial (YLST),
with results expected in coming years. Interim analysis
of ILST, presented at WCLC 2018, suggests PLCOm2012
outperforms USPSTF criteria with a 15.9% higher pro-
portion of lung cancers.44,45The worldwide burden of lung cancer is significant
and projected to increase in coming years, especially in
East Asia because of the significant population size, the
high stable incidence rates in males, and the significant
upward incidence trends in females.46,47 Additionally, a
significant proportion of lung cancers in East Asian
countries are in never-smokers with a female predomi-
nance.48 Currently, there are no validated risk prediction
tools for never-smokers or specifically for Asian pop-
ulations. The incorporation of other risk factors such as
outdoor and household air pollution and genetic sus-
ceptibility may improve the accuracy of lung cancer risk
prediction among Asian populations. Preliminary find-
ings from Myers et al.49 suggest there is significant as-
sociation between cumulative outdoor air pollution
exposure and lung cancer in female never-smokers as
well as a significant association between air pollution
and Asian ethnicity in never-smokers of both sexes. Such
findings may be important in the development of future
risk prediction models relevant to these populations.
An accurate risk assessment tool is important not
only for lung cancer screening but also for chemopre-
vention trials. Despite a rapidly increasing understand-
ing of the mechanisms of lung carcinogenesis, the
prevention of lung cancer has proven to be complicated.
To date, no phase III chemoprevention trial has shown
benefit and some trials have in fact shown harm in
current smokers.50 The availability of accurate lung
cancer risk assessment as well as accurate lung nodule
malignancy probability tools could allow the use of lung
cancer incidence as a primary endpoint, instead of in-
termediate lung cancer biomarkers, when testing for
promising chemopreventive agents within a lung cancer
screening setting using a smaller sample size and within
a shorter time frame than conventional phase III trial
designs.51Image-Based Screening
Screening for lung cancer through LDCT has been a
highly relevant and keenly debated topic in thoracic
oncology over the past 12 to 18 months. Although LDCT
screening is already available in some parts of the world,
primarily the United States, it has yet to be established
elsewhere. In Europe, the majority have been awaiting
the final mortality results of the NELSON study, a large
RCT powered to detect a reduction in lung cancer mor-
tality at 10 years.52 The final results of the NESLON trial
were presented at the plenary session of the WCLC in
September 2018 showing a 26% mortality reduction in
males (95% confidence interval [CI]: 0.60–0.91, p ¼
0.003) and 39% in females (95% CI: 0.35–1.04, p ¼
0.0543) at 10 years.5 This, combined with the pre-
existing evidence from NLST, provides robust evidence
1518 Balata et al Journal of Thoracic Oncology Vol. 14 No. 9that LDCT screening for lung cancer in high-risk pop-
ulations reduces disease-specific mortality. Subsequently
the IASLC, the largest global organization dedicated to
the study of thoracic malignancies, released a position
statement strongly recommending widespread imple-
mentation of LDCT lung cancer screening.53 The pre-
sented NELSON results also showed how stringent
nodule management algorithms can reduce the rate of
indeterminate and positive screening scan results, with a
rate of 9.3% and 2.2% respectively, thereby reducing
potential harms of screening.5 Additionally, the 10-year
results of the Italian MILD study were also presented
at the same congress and revealed a 39% overall
reduction in lung cancer–specific mortality (0.59; 95%
CI: 0.38–0.92).54 Final publications of both these studies
are still awaited and expected in the near future. A
further significant development from Europe was the
publication of the European Union (E.U.) position state-
ment on lung cancer screening.55 This detailed docu-
ment, co-authored by several experts with previous
experience in lung cancer screening trials, provides a
comprehensive summary of the evidence for LDCT
screening while at the same time highlighting matters
still needing to be addressed before widescale imple-
mentation across the continent. The statement concludes
with nine recommendations to guide the implementation
of lung cancer screening in Europe and expresses strong
support for LDCT screening by suggesting planning for
implementation to start within 18 months. Several pilot
studies and programs are already underway in Europe,
primarily in the United Kingdom, implementing lung
cancer screening for their local populations.56-58 A
common methodological approach between these pilot
programs is the novel use of lung health checks (LHC)
whereby ever-smokers are invited to have an assess-
ment, which can include a symptoms history, spirometry,
and tobacco addiction treatment, from which only thoseTable 1. Baseline Results From United Kingdom–Based Lung Ca
Pilot
LDCT Screening
Criteria LHC Participation
Lowes
Quinti
Manchester PLCOm2012  1.51% 9926 invited,
26.3% attendeda
75
Liverpoolb LLP  5% 13,761 invited,
40% attended
81
Londonb NLST;
LLP  2.5%; PLCOm2012
 1.51%
1997 invited,
50% attended
55
aMaximum capacity reached.
bOngoing programs.
LDCT, low-dose computed tomography; LHC, lung health check; Manchester, T
Project; London, Lung Screening Uptake Trial; SES, socioeconomic status; PLCOm
Liverpool Lung Project risk model; NLST, National Lung Screening Trial.most likely to benefit are offered LDCT screening. This
selection is performed through the incorporation of the
previously discussed lung cancer risk prediction models
into the LHCs. This approach, combined with substantial
public and primary care engagement, has shown
improved participation rates compared with previous
larger screening trials, especially among high-risk so-
cioeconomically deprived populations previously
described as hard-to-reach, and resulted in high lung
cancer detection rates (Table 1). The Manchester pro-
gram, which used the use of mobile CT units to access
some of the most deprived areas of the city, reported a
lung cancer detection rate of 4.4% across two screening
rounds of which 80% were early stage (I-II). Further-
more, having adopted the latest British Thoracic Society
nodule management guidelines, the Manchester in-
vestigators report an overall false-positive rate of 3.5%
(0.8% in the second round), defined as a proportion of
the screened population as a whole, and a benign sur-
gical resection rate of 2.5% (one case).59,60 The
encouraging results from these pilot studies have led to
strong support from NHS England with a recent
announcement of plans to rollout similar programs
across the country.61
In Asia, LDCT lung cancer screening is still under
consideration as the incidence of lung cancer among
never-smokers is higher compared to Europe and North
America.62,63 As discussed above, an estimated 10% to
30% of the lung cancers in Asia occur in never-smokers,
more so among females, and therefore countermeasures
for lung cancer in nonsmokers and light smokers are
important.64,65 A population-based cohort study aimed
to evaluate the effectiveness of lung cancer screening
using LDCT was conducted in Hitachi, Japan. The study
targeted the general population, including non-/light
smokers, aged 50 to 74 years, and investigated for lung
cancer incidence and mortality as well as all-causencer Screening Pilot Studies
t SES
le (%)
Proportion
Screened With
LDCT (%)
Baseline
Cancer
Detection Rate
(%)
Early Stage
(I-II) (%)
56 3.0 80
35 1.9 76
76 4.3 71
he Manchester Lung Health Check Pilot; Liverpool, Liverpool Healthy Lung
2012, Prostate, Lung, Colorectal and Ovarian trial risk model 2012 version; LLP,
September 2019 Prevention and Early Detection for Lung Cancer 1519mortality from both LDCT and chest x ray screening. The
study showed a 23% increase in lung cancer incidence
and a 51% reduction in lung cancer–specific mortality
with LDCT compared to chest x ray. Additionally, there
was a 43% reduction in all-cause mortality associated
with LDCT screening.62 In Korea, a pilot study of the
Korean Lung Cancer Screening Project (K-LUCAS), a
population-based single-arm trial targeting high-risk
populations (aged 55 to 74 years, 30 pack-year
smoking history, smoked within the last 15 years) was
conducted to evaluate the feasibility of implementing
Lung Imaging Reporting and Data System (Lung-RADS)
for LDCT screening.66 In this pilot study, 256 partici-
pants underwent LDCT screening and Lung-RADS was
used to categorize the findings. Overall, the distribution
of results between Lung-RADS categories 1, 2, 3, and 4
were 57%, 35.5%, 3.9%, and 3.5%, respectively. Positive
findings (category 3-4) were exhibited in 7.4% of par-
ticipants. Lung cancer was diagnosed in one participant
(stage IA, SCLC). Between 2017 and 2018, the K-LUCAS
project expanded to enroll 8000 participants a year at 14
institutions nationwide. As of November 2018, 13,491
participants have undergone LDCT screening with a scan
positivity rate of 15.3%. A total of 69 lung cancers have
been diagnosed of which 69.5% were early stage (I-II).
Subsequently, the Korean Ministry of Health and Welfare
announced that a nationwide lung cancer screening with
LDCT will start in July 2019.67 Although there have been
multiple lung cancer screening cohort studies in Asia, no
large-scale RCT has ever been conducted to date. A
Chinese study, The China National Cancer Early
Screening (CHANCES) Trial: Lung Cancer and Colorectal
Cancer, is expected to launch in the spring of 2019 with
the primary aims of (1) investigating the efficacy of LDCT
lung cancer screening in the reduction of lung cancer
mortality in high-risk population, (2) evaluating the
effectiveness of different screening intervals, and (3)
identifying an optimal protocol for lung cancer screening
in a Chinese population.68
Another eagerly discussed topic within image-based
lung cancer screening is the incorporation of modern
technology. Improving the accurate detection of pulmo-
nary nodules, reducing the rate of false-positive results
and improving the work efficiency of radiologists are
three major challenges for the implementation of LDCT
screening. Artificial intelligence, machine learning and
deep learning technologies have made rapid progress in
recent years. Several recent studies have shown that all
three technologies can significantly improve the detec-
tion rate of pulmonary nodules, including both nonsolid
and part-solid nodules, reduce the rate of missed cancer
diagnosis, and shorten reporting times of radiologists.69-72
After the detection of pulmonary nodules, such equipment
can also assist with both segmentation and accurate sizemeasurements.69,71 Furthermore, these technologies have
been shown to have the potential to assist with risk strat-
ification of pulmonary nodules, distinguishing between
benign and malignant nodules, as well as reducing unnec-
essary workup in a lung screening population.73-77 Further
data is expected over the coming year regarding the use of
technology within lung cancer screening protocols.Screening and Smoking Cessation
Successfully incorporating smoking cessation into
lung cancer screening programs is expected to reduce
lung cancer mortality over and above that achieved
by lung cancer screening alone and also has the potential
to improve cost-effectiveness.78,79 Widely regarded as a
potential teachable moment, LDCT screening offers a
critical opportunity to promote smoking cessation and
reduce further lung cancer morbidity and mortality.80,81
One concern, particularly in those who receive a negative
screening scan result, is the moral hazard of providing a
“license to smoke,” also referred to as a “health certifi-
cate effect.”82-84 While addressing smoking cessation in
the setting of lung cancer screening in the United States
is required by the Centers for Medicare and Medicaid
Services, widely recommended by national preventive
health experts and other related professional organiza-
tions and societies, best practices for integration and
implementation of evidence-based tobacco treatment in
the context of lung cancer screening are not well
defined.81,85 Data from the larger lung cancer screening
trials have shown mixed results with regard to the
impact of screening on smoking habits. NELSON data
suggested a possible negative impact on smoking as
screening was associated with a lower prolonged absti-
nence rate compared to the control group (14.5% versus
19.1%; odds ratio ¼ 1.40, 95% CI: 1.01–1.92; p <
0.05).86 The Danish DLCST trial showed no significant
positive or negative impact on smoking cessation from
screening.87 Encouragingly, recent data from the UKLS
trial has shown a positive impact of screening on
smoking cessation with quit rates of 14% versus 8% at 1
year and 24% versus 21% at 2 years in the intervention
versus control arms, respectively. The impact was
especially encouraging in those with a positive CT
result.88 Overall, rates of smoking cessation vary greatly
across lung cancer screening settings and there is
consensus that merely undergoing LDCT itself has little
effect on smoking cessation.89,90 Screening sites vary in
readiness and there are several reported barriers for
delivering high-quality tobacco treatment.91,92 Small pi-
lot studies testing smoking cessation interventions in the
context of lung cancer screening show promising re-
sults.93-95 There are several new initiatives examining
cost-effective implementation of tobacco treatment in
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has established the SCALE collaboration, a network of
randomized clinical trials testing various tobacco treat-
ment models in the context of lung cancer screening.96
Although data collection is ongoing, several of these
trials have recently published their clinical protocols and
study designs.97,98 In summary, despite the strong
endorsement that high-quality lung cancer screening
should include integration of evidence-based tobacco
treatment, the optimal approach for delivering feasible,
cost-effective, and sustainable cessation interventions in
the context of LDCT screening remains largely unknown.
Patient, provider, and systems levels barriers exist and
await further needed research on implementation pro-
cesses and outcome.Breath-Based Screening
Noninvasive biomarkers such as breath volatile
organic compounds (VOCs) and exhaled breath conden-
sate (EBC), consisting of both VOCs and non-VOCs, are
interesting to evaluate in a lung cancer screening setting.
Cancer alters the metabolism of patients, for example, by
increasing glycolysis and oxidative stress and the in-
duction of cytochrome P-450 (CYP450) enzymes, which
in turn alters the VOC and non-VOC compounds in
exhaled breath.99 Trained canines have been shown to
be able to discriminate lung cancer breath samples from
healthy individual and patients with COPD, but the
number of patients with solitary pulmonary nodules
(SPNs) or stage I disease have been low in previous
studies.100-104 A study specifically focusing on SPNs (30
patients, 79 controls) was presented at WCLC 2018 and
showed a sensitivity of 97% and specificity of 99%
(Table 2).105 These results are similar to previously
published studies which have included stage I-IV dis-
ease.100-104 As dogs need to be trained individually and
separately, and can have “off” days, bioengineered plat-
forms are preferred. Technical standards and pitfalls of
both VOC and EBC were discussed in depth in the
recently published European Respiratory Society tech-
nical standard.106 Previous EBC and VOC studies have
already shown promising results for lung cancer detec-
tion and were well summarized in three recent
reviews.104,107,108
VOC analysis and interpretation is usually based on
either evaluation of specific molecules by, for example,
gas chromatography–mass spectrometry or pattern
recognition of complex mixtures, also referred to as
“eNoses”; therefore, specific VOC compounds do not
need to be identified.109 In 2018, several studies were
presented or published on this topic and are also sum-
marized in Table 2.101,105,110-117 With the exception of
one study (de Vries et al.110), they all included patientswith a suspicion of or proven lung cancer. The percent-
age of patients with early-stage disease varied between
12% and 79%.101,105,111-117 In the study that included
patients without a suspicion of lung cancer, exhaled
breathprints were collected from 639 patients with
COPD who were managed according to standard care
and the incidence of lung cancer was monitored at 1 year
after sampling. The study showed a sensitivity of 80%
and a specificity of 90% for lung cancer prediction.110
The LuCID-study (NCT02612532) is an ongoing trial
that includes people who are referred for a lung cancer
diagnostic workup. VOCs are analyzed by the ReCIVA
breath sampler and the primary outcome is an improved
area under the curve for the optimal lung cancer
detection diagnostic algorithm. The study aims to
include 4000 participants overall, and as of the last up-
date at WCLC 2018, 1972 persons have been
included.118 Finally, proteomics analysis on EBC has
shown an area under the curve of 0.82 for discriminating
lung cancer patients (n ¼ 48, 6 with stage I-II) from
healthy controls (n ¼ 49).119 In 2018, two studies
evaluating EBC microRNAs for lung cancer detection
were presented at WCLC 2018 (Table 2).120,121Biofluid-Based Screening
Biomarkers of risk for lung cancer also have the po-
tential to improve early detection beyond the use of
imaging. MicroRNAs (miRNAs) control the expression of
key driver genes associated with tumorigenesis in
several cancer types and can be detected as stable
circulating molecules in body fluids. Deregulated miR-
NAs have been identified as potential biomarkers in
plasma from cancer patients. Circulating miRNAs have
been assessed as a candidate for early disease detection
in lung cancer. In a study presented at the WCLC 2018,
38 plasma samples from patients with lung adenocarci-
noma and squamous cell carcinoma and 21 healthy
controls from a screening population were profiled for
an 800-miRNA set using the Nanostring Counter plat-
form. Validation was performed in an independent
sample set of 40 patients and 40 controls, paired by age
and sex, using TaqMan quantitative real-time polymer-
ase chain reaction. A subset of 149 miRNAs were
significantly overexpressed in patient plasma compared
to controls, most common of which were associated with
the controlling the expression of tyrosine kinase, tran-
scription factors, and immune system–related genes
associated with lung tumorigenesis. In addition, three
distinct miRNA signatures with 12 unique miRNAs were
identified in the discovery set and validated in the in-
dependent sample set.122 These results contribute to the
identification of circulating plasma miRNAs as potential
biomarkers for early disease detection in lung cancer.
Table 2. Summary of Breath-Based Screening Approaches
Author
No.TotalPatients/
% NSCLC
% Stage I-II
NSCLC
No. and Type of
Controls
Type Breath
Test Sensitivity (%) Specificity (%) NPV (%) PPV (%) AUC of ROC
Dogs
Guirao
et al.105
30 / 100 100 18 COPD
61 healthy
1 Sniffer dog 97 99 99 97 0.985
Fischer-
Tenhagen
et al.101
9 / All lung cancer,
not specified
NA 10 healthy 2 Sniffer dogs (A
& B)
A: 100
B: 89
A: 80
B: 40
A: 100
B: 80
A: 82
B: 57
NA
eNoses /VOCs
Van de Goor
et al.117
60 / 85 12 107 Aeonose TS: 83
VS: 88
TS: 84
VS: 86
TS: 90
VS: 92
TS: 74
VS: 78
0.84
Tirzite
et al.116
252 / 86 34 122 Healthy,
101 benign lung
disease
Cyranose 320 S-: 96
Sþ: 96
S-: 91
Sþ: 92
S-: 96
Sþ: 94
S-: 91
Sþ: 94
NA
Huang
et al.111
56 / 98 79 188 Hospitalized for
other reason
Cyranose 320 LDA: 75
SVM: 83
LDA: 97
SVM: 86
LDA: 90
SVM: 93
LDA: 90
SVM: 93
LDA: 0.91
SVM: 0.90
Krauss
et al.115
55 / all lung cancer
(30 untreated, 25
in CR)
NA 25 Healthy
24 COPD
Aeonose 94 (Untreated
vs. healthy
control),
“all CR also
positive”
84 (Untreated
vs healthy
control)
NA
“COPD also
positive”
NA 0.95
Janssens
et al.112
56 / all lung cancer NA 28 COPD MCC/IMS 77 86 65 92 0.85
De Vries
et al.110
35 COPD patients
that developed
lung cancer <1
year of inclusion
NA 639 COPD SpiroNose 80 90 NA NA 0.91
Kort et al.114 107 / 100 NA 200 Healthy Aeonose All: 78
AC: 82
SCC: 85
All: 57
AC: 53
SCC: 78
All: 74
AC: 80
SCC: 95
NA All: 0.73
AC: 0.74
SCC: 0.80
Kort et al.113 18 / all SCLC NA 75 Healthy Aeonose 89 80 97 52 0.86
EBC
Spivack121 89 / 100 Predominantly 88 Smokers RTube
collection, 40
miRNA panel
analysis
NA NA NA NA miRNA: 0.64-
0.76
CM: 0.84
miRNAþCM:
0.86
Pattnaik
et al.120
NA / 100 NA NA RTube
collection,
Quantimir
qPCR
NA, “miRNAs
differentially
expressed in
NSCLC”
NA NA NA NA
COPD, chronic obstructive pulmonary disease; AC, adenocarcinoma; SCC, squamous cell cancer; NPV: negative prediction value; PPV: positive prediction value; AUC: area under the curve; ROC: receiver operating
curve; VOC: volatile organic compounds; NA: not available; TS: training set; VS: validation set; S-: non-smoking; Sþ: smoking; LDA: linear discriminant analysis; SVM: support vector machine analysis; CR: complete
remission; EBC: exhaled breath condensate; CM: clinical model; miRNA: microRNA
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1522 Balata et al Journal of Thoracic Oncology Vol. 14 No. 9Lung EpiCheck is a plasma-based test that detects lung
cancer–associated hypermethylation changes in six
markers in circulating free DNA using real-time poly-
merase chain reaction. In a recent study, EpiCheck was
performed on 689 patient samples (367 patients in the
training set, 322 patients in the test set), of which 283
patients had established cancer, and the rest served as
controls. The algorithm for calculating EpiScore as well
as the threshold for positivity were decided based on the
training set and then tested on an independent test set.
Specificity and sensitivity of EpIcheck performance score
was 94% and 74%, and 91% and 74% in the training set
and test set, respectively.6 These results require further
validation but provide an early glimpse into the promise
of plasma-based biomarkers as a screening tool for lung
cancer.Lung Cancer Diagnostics and Early
Treatment
Advances in Diagnostic Methods
SPNs identified through imaging requiring further
assessment can be a significant burden to health care
providers, both medically and economically, and should
prompt discussion and relevant assessments depending
on size, appearance, and location.123,124 Noninvasive
biomarkers may support nodule assessment in the
future, although their implementation requires longitu-
dinal validation.7 A definitive diagnosis requires tissue
sampling which can be achieved mostly by bronchoscopy
or transthoracic biopsy. Treatment with surgery or
radiotherapy without tissue sampling can also be
considered but needs to be carefully weighed against
procedural risks in a multidisciplinary team. Trans-
thoracic needle aspiration plays a significant role in the
investigation of pulmonary nodules due to its wide-
spread availability and relatively low invasiveness. The
diagnostic accuracy of transthoracic needle aspiration
depends on the size and location of the lesion, as well as
operator technique, and decreases from more than 90%
to 25% when the nodule size decreases to less than 1
cm.125 For nodules less than 2 cm, the total diagnostic
accuracy of a CT-guided biopsy is approximately 77%,
whereas for nodules measuring 0.5 cm to 0.7 cm in
diameter, sensitivity decreases to approximately 50%.126
The investigation of peripheral lung nodules remains a
challenge. Traditional bronchoscopy has poor perfor-
mance in locating and acquiring the required tissue from
peripherally positioned nodules (sensitivity, 20% to
84%). Ultrathin bronchoscopy (UTB), with an outer
diameter of 3 mm and an inner working channel diameter
of 1.2 mm, allows examination beyond that of the con-
ventional bronchoscope. A recent study for peripheral
pulmonary lesion investigation in 310 patients,combining either UTB or thin bronchoscopy, which has an
external diameter of 4 mm, with endobronchial ultra-
sound (EBUS), fluoroscopy, and virtual bronchoscopy
(VB) showed a higher diagnostic yield in UTB versus thin
bronchoscopy (74% versus 59%; p ¼ 0.044).127 Addi-
tionally, bronchoscopy may also be guided by virtual
systems. VB is a computer-guided bronchoscopy simula-
tion facilitated by preprocedural CT imaging. The diag-
nostic yield by UTB in combination with CT and VB is
reported to be 65.4% to 81.6%.128 Combining EBUS with
a guide sheath and VB results in a diagnostic yield of
63.3% to 84.4%, whereas combining x ray fluoroscopy
and VB has a diagnostic yield of 62.5% to 78.7%. The
overall performance of VB in a recent literature review
was reported to be 73.8%, reduced to 67.4% for lesions
less than or equal to 2 cm.129 Electromagnetic navigation
bronchoscopy (ENB) is an image-based technology that
uses VB and facilitates approaching peripheral lung le-
sions by means of electromagnetic fields.130 There are
two commercially available systems that provide ENB: i-
Logi (Covidien, Minneapolis, Minnesota) and SPiNDrive
(Veran Medical Technologies, Inc., St. Louis, Missouri). A
meta-analysis for the diagnostic yield for lung cancer of
ENB showed a sensitivity of 71.1% (95% CI: 64.6–76.8)
and a negative predictive value of 52.1% (95% CI: 43.5–
60.6).131 Radial probe endobronchial ultrasound may
overcome some of the limitations that exist with the
previously discussed methods as it allows real-time im-
aging of the target peripheral nodule and, in the hands of
an experienced bronchoscopist, can show a sensitivity of
70%.129 One of the main limitations of flexible bron-
choscopy is an inability to access and sample nodules that
are eccentrically positioned without an airway to
approach them. To overcome this, a novel navigational
approach known as bronchoscopic transparenchymal
nodule access (BTPNA) has been developed and recently
described.132 Currently, BTPNA relies heavily on operator
experience and equipment; further data are still required
and awaited. Robotic bronchoscopy systems are also be-
ing evaluated, and may offer an alternative approach that
can potentially overcome the above limitations.133
There are several novel methods of investigating
smaller but suspicious pulmonary nodules. The best
approach depends on several factors including location
of the nodule, presence or absence of a bronchus sign,
availability, operator experience, risk, and patient
preference.Conclusion
Despite significant advances in the management of
lung cancer, it remains the most common cause of
cancer-related mortality with poor overall survival out-
comes globally. There continues to be an urgent need for
September 2019 Prevention and Early Detection for Lung Cancer 1523the development of better prevention and early detection
strategies. Over the past year, results of the NELSON and
MILD trials have reinforced pre-existing evidence that
screening high-risk populations with LDCT can lead to
mortality reduction. The subsequent release of the IASLC
position statement strongly recommending LDCT
screening for lung cancer is an indicator that we might
be on the brink of widespread implementation. Beyond
screening, there has been a dramatic increase in dual and
poly-tobacco use with the recent emergence of other
tobacco products, including e-cigarettes. Although the
long-term effects of poly-tobacco use on lung cancer
remains unclear, there is an acceptance that efforts to
reduce the use of combustible cigarettes will result in a
decline in lung cancer morbidity and mortality. In 2018,
we witnessed results suggesting, for the first time,
superiority in the use of e-cigarettes compared to nico-
tine replacement therapy as a method for smoking
cessation. While these results are very encouraging,
more research is clearly needed to develop suitable
policies for appropriate and safe implementation of e-
cigarettes as a smoking cessation adjunct. Encouragingly,
there continues to be significant interest and ongoing
research in the topics of pre-neoplasia and chemopre-
vention, as outlined in this review. The identification and
development of various forms of biomarkers continues
to be an exciting area of lung cancer research and results
over the past 18 months have provided us with an early
glimpse into the promise of such biomarkers as a future
tool in the screening, diagnosis, and management of lung
cancer. At the same time, with ongoing advancements in
technology, great strides are being made in the devel-
opment of new and improved diagnostic methods for
investigation of early-stage lung cancer. Successful
implementation of new smoking cessation methods,
screening, and improved lung cancer diagnostics holds
great promise for an exciting future where lung cancer is
both a preventable and a curable disease.References
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